isoniazid, Nydrazid (discontinued), Laniazid (discontinued), INH (discontinued) (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
NURSING MOTHERS: Isoniazid is secreted into breast milk, however, it has not been reported to cause problems in nursing babies. Ultimately, the physician and the nursing mother must evaluate the risks and benefits of Isoniazid.
SIDE EFFECTS: When Isoniazid is broken down by the liver, one of the products is acetylhydrazine, a potent toxin for the liver. When taken over a long period of time at standard doses, Isoniazid can cause important and even fatal liver injury (hepatitis) in approximately 1 out of every 100 patients. Isoniazid-associated hepatitis usually occurs during the first three months of treatment but can occur at any time during therapy or even many months after starting treatment. Elevated blood liver tests occur in between 1 in 20 and 1 in 10 patients. Usually, enzyme levels return to normal despite continuation of the isoniazid, but in some cases progressive liver damage and even death occurs.
The risk of developing hepatitis is age-related. It occurs in less than 1 per 1,000 patients under 20 years of age, 3 per 1,000 patients 20-34 years of age, 12 per 1,000 patients 35-49 years of age, 23 per 1,000 patients 50-64 years of age, and 8 per 1,000 patients over 65 years of age. The risk of hepatitis is increased by daily consumption of alcohol. Among individuals who complete a full course of prophylaxis (prevention of tuberculosis), the hepatitis-related death rate (mortality) is 23-58 patients per 100,000 patients, far lower than the frequency of hepatitis. The mortality rate among individuals who develop symptoms of Isoniazid-induced hepatitis (not just minor abnormalities of liver tests) is approximately 10%. In one U. S. Public Health Service Surveillance Study involving 13,838 persons taking Isoniazid, there were 8 deaths among 174 cases of hepatitis, a mortality rate of 5%. There seems to be an increased risk of fatal hepatitis among women, particularly African-American and Hispanic women. The risk also may be increased during postpartum or immediately after pregnancy. Because of the risk of hepatitis, patients taking isoniazid should have their blood liver tests monitored monthly and should notify their physicians immediately if symptoms or signs of hepatitis arise. These symptoms and signs include unexplained loss of appetite, nausea, vomiting, dark urine, yellow skin or a yellowish tinge to the whites of the eyes, persistent fatigue, weakness or fever of greater than 3 days duration, or abdominal tenderness or discomfort, especially in the right upper part of the abdomen.
Damage to nerves (peripheral neuropathy) may occur with isoniazid and cause numbness and tingling of the hands or feet.
Other rare side effects of the nervous system include encephalopathy (inflammation of the brain), optic neuritis (inflammation of the nerve coming from the eye), atrophy (degeneration) of the nerve coming from the eye, seizures, impaired memory, psychosis. Pyridoxine (vitamin B6), 10-50 mg/day, decreases the risk of neural side effects.
The rate at which Isoniazid is eliminated by the liver is race-dependent. Thus, 60% of African Americans and whites eliminate Isoniazid slowly compared with only 10%-20% of Asians. Individuals who eliminate Isoniazid slowly are more prone to develop hepatitis and neural side effects with long-term use of Isoniazid.
Other side effects of Isoniazid include nausea, vomiting, abdominal pain, dry skin, fever, skin rashes and eruptions, swollen lymph nodes, reductions in white blood cells (which increases the risk of infection), reductions in platelets (which increases the risk of bleeding), anemia, high blood sugar levels in the blood, gynecomastia (enlargement of the breasts in men), ringing in the ears, urinary retention (difficulty passing urine), and painful joints.
Reference: FDA Prescribing Information
Last Editorial Review: 2/15/2012
Back to Medications Index
Get the latest health and medical information delivered direct to your inbox FREE!